

<p style="text-align: center;"><b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)</p> <p style="text-align: center;">JUL 27 2004</p> <p style="text-align: center;">PATENT &amp; TRADEMARK OFFICE</p>		ATTY DOCKET NO. 9516-083-999 (CAM: S01872-999082)	APPLICATION NO. 10/699,110
		APPLICANT Zeldis	
		FILING DATE 10-30-03	GROUP 1614

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	IF APPROPRIATE
ZF	10/105,833	03-25-02	Muller			
	10/243,927	09-13-02	Muller			
	10/316,673	12-11-02	Muller et al.			
	60/436,975	12-30-02	Muller et al.			
	60/438,448	01-07-03	Müller et al.			
	60/438,450	01-07-03	Muller et al.			
	60/438,450	01-07-03	Muller et al.			
	60/438,448	01-07-03	Muller et al.			
	60/452,460	03-05-03	Muller et al.			
	60/454,149	03-12-03	Muller et al.			
	60/454,155	03-12-03	Muller et al.			
	60/454,149	03-12-03	Man et al.			
	10/798,372	03-12-03	Man et al.			
	10/392,195	03-19-03	Schäfer et al.			
	10/392,195	03-19-03	Muller et al.			
	10/462,319	06-16-03	Muller et al.			
	10/622,618	07-17-03	Muller et al.			
	10/685,942	10-14-03	Man et al.			
	10/715,184	11-17-03	Muller et al.			
	10/748,085	12-29-03	Man et al.			
	10/786,822	02-25-04	Man et al.			
	10/794,931	03-05-04	Muller et al.			
ZF	3,536,809	10-27-70	Applezweig			
	3,598,123	08-10-71	Zaffaroni			
	3,845,770	11-05-74	Theeuwes et al.			
	3,916,899	11-04-75	Theeuwes et al.			
	4,008,719	02-22-77	Theeuwes et al.			
ZF	5,059,595	10-22-91	La Grazie			

Z.F	A30	5,073,543	12-17-91	Marshall et al.			
	A31	5,120,548	06-09-92	McClelland et al.			
	A32	5,354,556	10-11-94	Sparks et al.			
	A33	5,463,063	10-31-95	Muller			
	A34	5,591,767	01-07-97	Mohr et al.			
	A35	5,605,914	02-25-97	Muller			
	A36	5,632,984	05-27-97	Wong et al.			
	A37	5,639,476	06-17-97	Oshlack et al.			
	A38	5,658,940	08-19-97	Muller et al.			
	A39	5,674,533	10-07-97	Santus et al.			
	A40	5,698,579	12-16-97	Muller.			
	A41	5,703,098	12-30-97	Muller			
	A42	5,728,844	03-17-98	Muller			
	A43	5,728,845	03-17-98	Muller			
	A44	5,733,566	03-31-98	Lewis			
	A45	5,736,570	04-07-98	Muller			
	A46	5,770,589	06-23-98	Billson			
	A47	5,801,195	09-01-98	Muller et al.			
	A48	5,877,200	03-02-99	Muller			
	A49	5,929,117	07-27-99	Muller et al.			
	A50	5,968,945	10-19-99	Muller et al.			
	A51	6,001,368	12-14-99	Jenks			
	A52	6,011,050	01-04-00	Muller et al.			
	A53	6,015,803	01-18-00	Wirostko			
	A54	6,020,358	01-04-00	Muller et al.			
	A55	6,046,221	04-04-00	Muller et al.			
	A56	6,130,226	10-10-00	Muller et al.			
	A57	6,180,644	01-30-01	Muller et al.			
	A58	6,200,987	03-13-01	Muller			
	A59	6,214,857	04-10-01	Muller et al.			
	A60	6,218,369	04-17-01	Bombardelli et al.			
	A61	6,225,348	05-01-01	Paulson			
	A62	6,262,101	07-17-01	Muller et al.			
	A63	6,284,780	09-04-01	Muller et al.			
	A64	6,326,388	12-04-01	Man et al.			
	A65	6,429,221	08-06-02	Muller et al.			
	A66	6,479,554	11-12-02	Muller et al.			
Z.F	A67	6,518,281	02-11-03	Muller et al.			

	A68	6,656,964	12-02-03	Muller et al.			
	A69	6,667,316	12-23-04	Man et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	YES	NO
Z.F	A70	WO 03/080048	10-02-03	PCT					
	A71	WO 03/080049	10-02-03	PCT					
	A72	WO 01/34606	05-17-01	PCT					
	A73	WO 01/45702	06-28-01	PCT					
	A74	WO 95/01348	01-12-95	PCT					
	A75	WO 97/08143	03-06-97	PCT					
	A76	WO 97/23457	07-03-97	PCT					
Z.F	A77	WO 99/06041	02-11-99	PCT					

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

Z.F	A78	1 Burger's Medicinal Chemistry and Drug Discovery, 172-178, 949-982 (Manfred E. Wolff ed., 5th ed. 1995)
Z.F	A79	Corral, et al., Ann. Rheum. Dis. 58:(Suppl I) 1107-1113 (1999)

EXAMINER	Zehn F Fay	DATE CONSIDERED
----------	------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## FOREIGN PATENT DOCUMENTS

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**


EXAMINER	Zahn Fay	DATE CONSIDERED	4/28/07
----------	----------	-----------------	---------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<p style="text-align: center;"> <b>LIST OF REFERENCES CITED BY APPLICANT</b>          (Use several sheets if necessary)       </p>	ATTY DOCKET NO.	APPLICATION NO.
	9516-083-999	10/699,110
	APPLICANT	Zeldis
FILING DATE	GROUP	
October 30, 2003	1614	


## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

PROSPECTIVE DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES
							NO

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

Z. F	A84	Bressler, 1999, "Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP Report 1," Archives of Ophthalmol. 117(10):1329-1345
Z. F	A85	Hunt, 2002, Rostaporfin (Miravant Medical Technologies) IDrugs 5(2):180-186
Z. F	A86	Ohno-Matsui et al., 2001, "Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors FEGF and PEDF," J. Cell. Physiol. 189(3):323-333

EXAMINER		DATE CONSIDERED	4/28/07
----------	---	-----------------	---------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.